BlueLinx Bears Circle Ahead of Q3 Print
Produced automatically from ORTEX data and published under the ORTEX News editorial standards set by Peter Hillerberg, Editor, ORTEX News. How we publish
BlueLinx Holdings heads into its Q3 earnings release with short sellers building positions at the fastest pace in months, even as the stock drops sharply into the report.
Short interest has become the defining feature of the setup. Bearish positions climbed 16% in one week to 6.3% of the free float, reaching their highest level in the 30-day window tracked here. The move is not random: it accelerated in the final week of October, with shorts adding roughly 70,000 shares between October 22 and October 26 alone. The borrow market remains extremely loose, with availability at 7,624%, meaning there is no constraint on further short building. Cost to borrow is just 1.1%, posing no squeeze risk for new entrants. The stock itself fell 7.8% on November 3, its sharpest single-day drop in recent months, pulling it to $72.56 and extending a 5% weekly loss.
Options positioning offers a mild counterpoint. The put/call ratio of 0.20 is barely above its 20-day average and sits near the low end of its 52-week range of 0.06 to 0.61. Options traders are not pricing in the same degree of fear as the short sellers, suggesting the two groups are reading the same setup differently.
The bull and bear debate centres on how durable BlueLinx's recent momentum is. Bulls point to the Specialty product mix, now around 70% of sales, carrying gross margins 800 to 1,000 basis points above Structural. The Q2 beat with adjusted EPS of $1.15 and EBITDA of $36 million, alongside five consecutive quarters of year-on-year revenue growth, underpin the case for market share gains. The Disdero acquisition and Trex distribution deal add further optionality. Bears counter with a deteriorating demand backdrop: single-family starts under pressure, 30-year mortgage rates near 7%, and roughly 60 vendor price increases through the first half of 2026. Conservative estimates for full-year AEBITDA sit around $94 million against a consensus of $106 million, a gap wide enough to matter. Analyst coverage remains thin and mixed. After DA Davidson moved to Neutral in mid-2025 and Citizens initiated at Market Perform in September, the consensus sits at Hold. Benchmark maintains a Buy with an $83 target, the most constructive voice on the register.
The most noteworthy insider action in the 90-day window was Director Kim Fennebresque's open-market sale of 34,138 shares at $84.15 on August 6, netting roughly $2.9 million. That was a discretionary disposal, not a 10b5-1 plan sale, executed the morning after the Q2 beat sent the stock sharply higher. No activist holders appear on the 13D register. BlackRock's 13G stake disclosed a reduction from 11.8% to 7.9% in an April filing, though institutional-level positions move on different timescales and the data is as-last-disclosed.
The Q3 print will test whether the demand signals that drove the Q2 beat have held through a quarter shaped by rising mortgage rates, lumber cost pressures, and a housing market still searching for its floor.
Stocks in this article
See the live data behind this article on ORTEX.
Open BXC on ORTEX →How this article was generated
- Generated
- 4 Nov 2026, 04:23
- Data as of
- 4 Nov 2026, 04:01
- Prompt version
- v1.0
- Data sources
- Short interestCost to borrowUtilizationOptions flowEarningsInstitutional positioningORTEX Alpha signalsRecent ORTEX notes
ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data and reviewed by the ORTEX team. Content is informational only and does not constitute investment advice.